Mr. Serge Verreault reports

CRESCITA TO ACQUIRE STRATEGIC ASSETS OF OCCY LABORATORY

Crescita Therapeutics Inc. has agreed to acquire all of the non-real-estate business assets of Occy Laboratory Inc., a Laval-based manufacturer and distributor of high-quality dermocosmetic products.

The transaction, conducted pursuant to the voluntary proceedings undertaken by Occy under the Bankruptcy and Insolvency Act, is expected to enhance Crescita's position in the Canadian skin care market by expanding its product offering and customer network and represents a further step in the execution of Crescita's growth plan. The acquired assets include Occy's manufacturing equipment, inventory customer network and intellectual property.

"This tuck-in acquisition aligns with our long-term vision to become a leading Canadian skin care company," stated Serge Verreault, president and chief executive officer of Crescita. "We are pleased to expand our skin care portfolio with Aquafolia, Occy's lead product line. This brand's distinctive identity lies in its use of natural anti-aging biotechnologies to formulate high performance skin care and is complementary to our existing portfolio. We believe that this transaction strengthens Crescita's position and product offering in our markets, underscoring our commitment to delivering exceptional skin care solutions to our customers. We look forward to leveraging the new assets to drive future growth and innovation," concluded Mr. Verreault.

The transaction received a vesting and approval order rendered by the Quebec Superior Court at a sale approval hearing on June 19, 2024, and is expected to close shortly thereafter, subject only to customary closing conditions.

Crescita will continue the commercial activities carried on by Occy prior to closing while it integrates the assets into its operations in the coming months. Crescita will provide financial information following the closing of the transaction.

About Crescita Therapeutics Inc.

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D (research and development) and manufacturing capabilities. The company offers a portfolio of high-quality, science-based, non-prescription skin care products and a commercial-stage prescription product. The company also owns multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin.